anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study presents several accounts of user experiences with assistive technology (AT). Although previous studies on dyslexic students reported promising results from using audiobooks, text-to-speech (TTS), and speech-to-text (STT), qualitative research is relatively sparse and short-term, and little is known about adolescents' long-term experiences of using AT in schools. Therefore, this five-year follow-up study aimed to describe dyslexic students' experiences of AT.
MATERIALS AND METHODS: Nine students with dyslexia were interviewed using a semi-structured framework and a descriptive pattern-based thematic analysis. The students had previously participated in an AT intervention in Sweden.
RESULTS: Three main themes are reported: Contextual factors: facilitators or barriers; Emotional responses in the learning environment; Developing meaningful strategies. The results align with previous research findings that audiobooks are beneficial throughout the school years, while STT is of mixed utility. TTS was mainly used in learning to decode texts. Continued AT use is discussed thematically, concretising experiences connected to schools' multilevel support.
CONCLUSIONS: This study can contribute to the development of AT academic practices enriched by users' views. The findings reveal factors enabling or hindering students' continued AT usage. Contextual factors in schools concern organisational elements rather than AT accessibility. Students' emotional responses (using AT in the classroom) are influenced by dyslexia self-acceptance and AT attitudes. Students' understanding of how and why to use AT may limit the development of meaningful strategies. Implications and suggested further research are provided to improve dyslexic students' AT experiences and success in school.
PURPOSE:To obtain an antiplatelet agent useful for the treatment of various thrombotic diseases by using a 3-(2H)-pyridazinone derivative as an active component. CONSTITUTION:A compound of formula (X is Cl or Br; Y is H, Cl, Br, NO2, NH2, 1-4C alkylamino, OH, SH, 1-8C alkoxy, phenoxy, etc.; Ar is (substituted) phenyl, naphthyl, benzyl, thienyl, pyridyl, etc.) or its salt is used as an active component of the objective agent. The agent is useful for the treatment of diseases caused by thrombogenesis such as cerebral thrombosis, pulmonary thrombosis, myocardial infarction, stenocardia and peripheral artery occlusion. It can be used in the form of injection, ointment, suppository, aerosol, tablet, capsule, granule, pill, syrup, solution, emulsion, suspension, etc. The content of the compound of formula in the agent is 0.1-99.5% and the compound is administered at daily rate of 0.003-1.5g for adult.
BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard chemoimmunotherapy regimens in multiple randomized trials but is limited by cardiovascular side effects such as atrial fibrillation and hypertension. Second-generation BTKis have improved selectivity and demonstrate reduced rates of cardiovascular complications in 3 head-to-head ibrutinib studies. The emergence of BTK C481S mutation has led to the development of noncovalent, "reversible" BTKis, such as pirtobrutinib, which are agnostic to the C481S mutation. However, these inhibitors are associated with resistant mutations outside the C481 hot spot. These variant non-C481 mutations are of great clinical interest because some are shared among pirtobrutinib, zanubrutinib, and acalabrutinib, with potential implications for cross resistance and treatment sequencing. Finally, BTK protein degraders with in vitro activity against C481 and non-C481 mutations are currently in clinical development. Here, we review the evolution of therapeutic BTK-targeting and discuss future directions for clinical research.
In eukaryotes, Hsp90B1 serves as a vital chaperonin, facilitating the accurate folding of proteins. Interestingly, Hsp90B1 exhibits contrasting roles in the development of various types of cancers, although the underlying reasons for this duality remain enigmatic. Through the utilization of the Drosophila model, this study unveils the functional significance of Gp93, the Drosophila ortholog of Hsp90B1, which hitherto had limited reported developmental functions. Employing the Drosophila cell invasion model, we elucidated the pivotal role of Gp93 in regulating cell invasion and modulating c-Jun N-terminal kinase (JNK) activation. Furthermore, our investigation highlights the involvement of the unfolded protein response-associated IRE1/XBP1 pathway in governing Gp93 depletion-induced, JNK-dependent cell invasion. Collectively, these findings not only uncover a novel molecular function of Gp93 in Drosophila, but also underscore a significant consideration pertaining to the testing of Hsp90B1 inhibitors in cancer therapy.
In this study, one channel of the stimulation device will provide active stimulation to the patient, while the second channel will not be connected. The patient won't know which channel is active. Both channels will use continuous mode with a pulse frequency of 20 Hz and a pulse width of 200 ms. The intensity for the active channel will be adjusted based on comfort level and observed hallux reaction. Treatment includes 20 sessions of 30 minutes each, administered five times a week for four weeks.
The invention provides a rhodiola rosea compound effervescent tablet with lung cancer preventing effect and a preparation method thereof. The effervescent tablet is composed of the following components in parts by weight: 10-20 parts of rhodiola rosea extract, 5-15 parts of taurine, 10-20 parts of inulin, 27 parts of anhydrous citric acid, 26 parts of sodium hydrogen carbonate, 0.2 part of lemon essence, 0.3 part of povidone K30 and 5 parts of PEG6000. The rhodiola rosea compound effervescent tablet beverage is processed and made by adopting rhodiola rosea as a main raw material and adding plant extracts such as inulin, and various effects are complementary, so that effects of the rhodiola rosea are played to the utmost extent, the preparation method is simple and easy, and the lung cancer can be prevented better. The rhodiola rosea is prepared into effervescent tablet beverage, so that the rhodiola rosea has better absorption effect and taking experience. The effervescent tablet can be rapidly disintegrated after meeting water, is convenient to take and is especially applicable to children, the aged and patients difficult to swallow pills. The inulin in the rhodiola rosea effervescent tablet also enables taste of the beverage to be better, and the rhodiola rosea can be assisted to play better curative effect.
Individuals with ADHD have altered reinforcement/motivational functioning that are likely related to risk for smoking and recalcitrance for quitting. The investigators lab has demonstrated that the abstinence-induced reinforcing effects of cigarette smoking are more pronounced in ADHD smokers. However, in spite of these increases and demonstrated differences in withdrawal severity, interventions that provide reinforcement contingent on abstinence appear to work well for smokers with ADHD. To date, no studies have explicitly investigated how motivational processes are associated with smoking cessation attempts in ADHD smokers. The proposed pilot research is therefore highly innovative since it will evaluate how these processes change and influence outcomes during two different kinds of smoking cessation interventions. The project will also provide important pilot data on potential differences between ADHD and non-ADHD smokers in the context of a contingency management (CM) trial, which will help guide the development of more refined and targeted cessation interventions for this high risk group of smokers.
PURPOSE:To provide an antimycotic agent containing a specific ketene S,S-acetal as an active component and useful for the remedy of mycoses of man and animal. CONSTITUTION:The objective antimycotic agent contains the compound of formula I (R is H, 1-8C alkyl, 3-6C cycloalkyl, halogen, etc.) as an active component. The compound of formula I can be produced by reacting 1- cyanomethylimidazole of formula IV with CS2 in the temperature and reacting the resultant intermediate of formula III with an alkyl dihalide of formula II (X is halogen, mesyloxy, etc.) without separating the intermediate from the reaction system. The compound of formula I can be used for the remedy of local mycosis, mucous infection and systemic mycosis caused by fungi belonging to Trichophyton genus or Candida genus.
Potassium chloride extended-release tablets, USP contain 600 mg, 750 mg and 1500 mg of potassium chloride (equivalent to 8 mEq, 10 mEq and 20 mEq, respectively). Potassium chloride extended-release tablets, USP are provided as extended-release, film-coated tablets. Potassium chloride extended-release 600 mg tablets are round in shape, yellow in color and are debossed with the trademark K-TAB on one side. Potassium chloride extended-release 750 mg tablets are ovaloid in shape, yellow in color and are debossed with the “a” logo on one side and the trademark K-TAB on the other side. Potassium chloride extended-release 1500 mg tablets are ovaloid in shape, white in color and are debossed with the trademark K-TAB on one side. 

Potassium chloride extended-release tablets are supplied as follows: 

10 mEq
Cohort C will include healthy participants aged 18 to 55 years. Cohort D will include healthy elderly participants aged ≥ 56 years. In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2). At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
Progression of scoliosis can occur in patients who experience rapid growth. Because somatropin increases growth rate, patients with a history of scoliosis who are treated with somatropin should be monitored for progression of scoliosis. However, somatropin has not been shown to increase the occurrence of scoliosis. Skeletal abnormalities including scoliosis are commonly seen in untreated Turner Syndrome patients. Scoliosis is also commonly seen in untreated patients with Prader-Willi Syndrome. Physicians should be alert to these abnormalities, which may manifest during somatropin therapy.
The available evidence suggests that there are opportunities to optimize the primary care of patients with ACD. We are proposing to build upon the current evidence and guidelines for disease management programs, our existing specialized resources, our existing primary care practices, and develop and test a model of care that is primary care based, sensitive to the unique demands and characteristics of different primary practices. Our goal is to design linkage and care strategies of relevance and importance to the primary care providers who care for patients with advanced COPD and CHF.

The study is a randomized controlled clinical trial of the RoadMAP program (intervention) delivered by a PCNS compared to usual care (control group). The primary outcome will be degree of adherence to clinical practice guidelines. Secondary outcomes will be patient satisfaction, quality of life, use of community-based services, number of emergency room visits, and number of hospitalizations. The purpose of the RoadMAP program is to improve the care of people with advanced stage COPD and CHF. Specifically, activities will be aimed at improving patients' self care ability, facilitating access to the most appropriate services, ensuring medical treatment according to consensus guidelines and promoting consistency of health care communication. Adherence to guidelines is a process that involves activities by the patient, PCNS, and the Primary Care Physician. The PCNS would follow-up the patient again at approximately one month after initial contact and then every 3 months, to assess and monitor adherence to the proposed MAP by the patient, the physician, and the nurse. Patients will have the option of returning to the physician office or to be monitored by phone. An office visit will be recommended if there is a perceived need for medical assessment and intervention. The family physician would continue to see the patient as required in order to carry out the medical portion of the MAP and to deal with other primary care problems as needed. Additionally, the PCNS would be available to work with nurses and other health professionals in each primary care practice in the provision of care to the ACD patients.
Arm 2 Intervention Type: Drug Intervention Name: Zinc sulfate Other Intervention Names: Zinc Intervention Description: Patients will receive zinc sulfate capsules (25mg) thrice daily at 8-hour intervals. The treatment will start 3 days before the beginning of radiotherapy and continue for 2 weeks after the completion of the radiotherapy schedule.
Pulmonary fibrosis is a fatal and chronic lung disease that is characterized by accumulation of thickened scar in the lungs and impairment of gas exchange. The cases with unknown etiology are referred as idiopathic pulmonary fibrosis (IPF). There are currently no effective therapeutics to cure the disease; thus, the investigation of the pathogenesis of IPF is of great importance. Recent studies on bone morphogenic proteins (BMPs) and their receptors have indicated that reduction of BMP signaling in lungs may play a significant role in the development of lung fibrosis. BMPs are members of TGF-β superfamily, and they have been shown to play an anti-fibrotic role in combating TGF-β-mediated pathways. The impact of BMP receptors, in particular BMPR2, on pulmonary fibrosis is growing attraction to researchers. Previous studies on BMPR2 have often focused on pulmonary arterial hypertension (PAH). Given the strong clinical association between PAH and lung fibrosis, understanding BMPs/BMPR2-mediated signaling pathway is important for development of therapeutic strategies to treat IPF. In this review, we comprehensively review recent studies regarding the biological functions of BMPs and their receptors in lungs, especially focusing on their roles in the pathogenesis of pulmonary fibrosis and fibrosis resolution.
The invention relates to a preparation method of traditional Chinese medicine for treating blood-deficiency-type ecthyma, which belongs to the technical field of traditional Chinese medicine preparation method. The existing way for treating the blood-deficiency-type ecthyma generally adopts antibiotics and sulfonamides. If piperacillin is adopted for treating the blood-deficiency-type ecthyma, people have local pain after the intramuscular injection, and adverse reactions such as temporary nausea, sense of suppression in the chest, cough, fever, bad breath, and bloody eyes are caused after the rapid venous injection. The technical scheme adopted by the invention is that: glossy ganoderma, donkey-hide gelatin, polygonum multiflorum, Chinese angelica, prepared rehmannia root, radix paeoniae alba, longan pulp, dry gingers, dried longan pulp, rhizoma atractylodis macrocephalae, American ginseng, lotus seeds, codonopsis pilosula, sharpleaf galangal fruits, astragalus mongholicus, rhizoma polygonati, black-bone chicken, polished round-grained rice, wild cabbage, Chinese dates, yams, chicken yellow and liquorice are placed in the water to be soaked and then to be decocted with slow fire, and the decocted liquid medicine is the traditional Chinese medicine for treating the blood-deficiency-type ecthyma. The preparation method has the advantages that the traditional Chinese medicine is simple to prepare, and the prepared traditional Chinese medicine has small toxic and side effects, short course of treatment and high curative rate. Moreover, adverse reaction caused by the Western medicine can also be avoided.
After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
The present invention relates to a cleaning composition comprising coffee cherry by-products and a use thereof. According to the cleaning composition of the present invention, coffee cherry by-products can be effectively recycled, and the cleaning power can be increased by nutrients such as amino acids such as organic acids, aspartic acids, etc. water-soluble minerals, trace elements, etc. contained in coffee cherry by-products. In addition, by further including other natural extracts in the cleaning composition of the present invention, it is possible to provide a cleaning composition that has excellent cleaning power and foaming power and can also have an antibacterial effect at the same time. Furthermore, provided are a dishwashing detergent and hand sanitizer in which the slippery and skin irritation left on the hand after use of the cleaning composition of the present invention is reduced, and a fragrance unique to natural substances is added.
The invention describes catabolism of Aβ by endothelin converting enzymes (ECEs). Methods of identifying compounds that upregulate ECEs are provided by the invention. Further provided by the invention are methods of regulating Aβ catabolism in a cell and methods of decreasing the amount of Aβ in a cell. The invention discloses methods of diagnosing an individual with AD and methods of treating such an individual. The invention further discloses methods of identifying compounds that have anti-hypertension acitivity but do not cause an increase in the level of Aβ. Further, the invention provides mutant ECE nucleic acids and mutant ECE polypeptides.
During pregnancy, women regularly interact with healthcare professionals, an often untapped resource and opportune time to minimize stress and optimize weight gain, nutrition, and activity, positively impacting outcomes and lifelong health. The overarching hypothesis of this study is that a simple, personalized, smartphone-based activity intervention using a wrist-based activity tracker will help high risk pregnant women increase their activity level during pregnancy, reduce stress, and optimize gestational weight gain and biometric parameters. Importantly, the investigators propose that women can be engaged in care via a simple, personalized text-message based intervention.

Women will be enrolled early in pregnancy and followed prospectively. All women will receive a wrist-based activity tracker. Some women (those randomized to receive individualized counseling) will receive weekly text messages based on their activity and sleep in the prior week. Other women will not receive any specific instructions regarding activity level. The investigators will follow their outcomes prospectively. Biologic samples (including blood, urine, vaginal swabs, placental tissue) will be collected at enrollment and at delivery.
Mammalian heart is capable to regenerate almost completely early after birth through endogenous cardiomyocyte proliferation. However, this regenerative capacity diminishes gradually with growth and is nearly lost in adulthood. Cannabidiol (CBD) is a major component of cannabis and has various biological activities to regulate oxidative stress, fibrosis, inflammation, and cell death. The present study was conducted to investigate the pharmacological effects of CBD on heart regeneration in post-MI mice. MI models in adult mice were constructed via coronary artery ligation, which were administrated with or without CBD. Our results demonstrate that systemic administration (10 mg/kg) of CBD markedly increased cardiac regenerative ability, reduced infarct size, and restored cardiac function in MI mice. Consistently, in vitro study also showed that CBD was able to promote the proliferation of neonatal cardiomyocytes. Mechanistically, the expression of miR-143-3p related to cardiomyocyte proliferation was significantly down-regulated in CBD-treated cardiomyocytes, while the overexpression of miR-143-3p inhibited cardiomyocyte mitosis and eliminated CBD-induced cardiomyocyte proliferation. Moreover, CBD enhanced the expression of Yap and Ctnnd1, which were demonstrated as the target genes of miR-143-3p. Silencing of Yap and Ctnnd1 hindered the proliferative effects of CBD. We further revealed that inhibition of the cannabinoid receptor 2 impeded the regulatory effect of CBD on miR-143-3p and its downstream target Yap/Ctnnd1, which ultimately eliminated the pro-proliferative effect of CBD on neonatal and adult cardiomyocytes. Taken together, CBD promotes cardiomyocyte proliferation and heart regeneration after MI via miR-143-3p/Yap/Ctnnd1 signaling pathway, which provides a new strategy for cardiac repair in adult myocardium.
This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
The aim of the MOV-E-STAR project is to promote mental health in early adolescents (12-15 years) by motivating them to adopt a healthy lifestyle. Adolescents can protect their mental health by increasing physical activity, reducing sitting time, getting sufficient sleep, and taking a daily breakfast. Targeting these healthy lifestyle behaviours in young adolescents is an empowering, low-threshold approach that can create large public health effects. The MOV-E-STAR project aims to meet the need for an intervention targeting these behaviors in the adolescent population. Therefore, the mobile intervention '#LIFEGOALS' was developed in collaboration with stakeholders and users. The theory-based intervention consists of an application that includes (a) a self-regulation component for goal setting, self-monitoring and feedback, (b) a narrative in the form of short episodes from a youth daily drama for modelling, attitude change and increased engagement, and (c) an automated chat-function for social support and sustained engagement with the intervention.

The current study will test the intervention in a group-randomized controlled trial for its effects on mental well-being. Participants in the intervention group will have the #LIFEGOALS intervention installed on their phone and will be asked to use the intervention for 12 consecutive weeks. Participants in the control group will not receive an intervention but will only participate in the measurements. Outcomes will be assessed at baseline, intermittent (7 weeks after baseline) and post (13 weeks after baseline). Measures will include smart wearables and surveys.
PURPOSE: A composition including a polyacetylene compound or extract of Petrosia sp. is provided to have growth-suppressing activation effect to cancer cells, thereby being used as a pharmaceutical composition for treating and preventing cancer cells. CONSTITUTION: A composition including a polyacetylene compound or extract of Petrosia sp. is represented by chemical formula 1. The polyacetylene-based compound has three hydroxy groups. The polyacetylene compound has hydroxy groups at the third, 16th, and 28th positions. A pharmaceutical composition for treating and preventing cancer contains the compound or a pharmaceutically acceptable salt as an active ingredient. The amount of the compound is 0.1-50 wt%, based on the total weight of the composition.